Advanced search
Start date
Betweenand

Comparison between Neovascularization and Cellular Hypermetabolism in Multiple Myeloma Using 68Ga-PSMA and 18F-FDG PET/CT Imaging - A Pilot Study

Abstract

18F-FDG PET/CT has been used in the management of patients with multiple myeloma (MM) in staging, restaging and therapy assessment. Nevertheless, false negative results are reported mainly in patients with diffuse bone marrow infiltration or with lesions with low glycolyitc metabolic activity. This situation encourages search for more accurate positron emitters radiopharmaceuticals. On the other hand, with the development of new technologies based on multiparametric cytometry that are able to detect 0.001 percent of plasmocytes in bone marrow, both techniques have been considered in therapy assessment in MM. Recently, the radiopharmaceutical 68Ga-PSMA has been developed, theoretically a prostate specific membrane antigen used to detect prostate cancer lesions but it has been reported that this tracer is also an excellent neoangiogenesis marker that can be taken up by a variety of neoplasias besides prostate cancer. There are already reports of incidental finding of markedly increased 68Ga-PSMA uptake in multiple myeloma lesions. However, there are not prospective series in the literature evaluating the ability of 68Ga-PSMA PET/CT in detecting active multiple myeloma lesions. If this diagnostic ability could be comprovated and, eventually its superiority compared to 18F-FDG PET/CT imaging, 68Ga-PSMA PET/CT may contribute to improve accuracy of MM staging and to result in potential strategies alteration in disease management. Moreover, the demonstration of intense uptake of this radiopharmaceutical in MM patients may encourage the evaluation of a new therapeutic option for these patients, the radioisotopetherapy with 177Lu-PSMA or 225Ac-PSMA that showed very promissing results in patients with castrate-resistant metastatic prostate cancer. (AU)

Articles published in Agência FAPESP Newsletter about the research grant:
Articles published in other media outlets (0 total):
More itemsLess items
VEICULO: TITULO (DATA)
VEICULO: TITULO (DATA)

Scientific publications
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
TAKAHASHI, MARIA E. S.; MOSCI, CAMILA; SOUZA, EDNA M.; BRUNETTO, SERGIO Q.; DE SOUZA, CARMINO; PERICOLE, FERNANDO V.; LORAND-METZE, IRENE; RAMOS, CELSO D. Computed tomography-based skeletal segmentation for quantitative PET metrics of bone involvement in multiple myeloma. NUCLEAR MEDICINE COMMUNICATIONS, v. 41, n. 4, p. 377-382, APR 2020. Web of Science Citations: 0.
CAMACHO, MARIANA R.; ETCHEBEHERE, ELBA; TARDELLI, NATALIA; DELAMAIN, MARCIA T.; VERCOSA, ALINE F. A.; TAKAHASHI, MARIA E. S.; BRUNETTO, SERGIO Q.; METZE, IRENE G. H. L.; SOUZA, CARMINO A.; CERCI, JULIANO J.; RAMOS, CELSO D. Validation of a Multifocal Segmentation Method for Measuring Metabolic Tumor Volume in Hodgkin Lymphoma. JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY, v. 48, n. 1, p. 30-35, MAR 1 2020. Web of Science Citations: 0.
TAKAHASHI, MARIA E. S.; MOSCI, CAMILA; SOUZA, EDNA M.; BRUNETTO, SERGIO Q.; ETCHEBEHERE, ELBA; SANTOS, ALLAN O.; CAMACHO, MARIANA R.; MIRANDA, ELIANA; LIMA, MARIANA C. L.; AMORIM, BARBARA J.; DE SOUZA, CARMINO; PERICOLE, FERNANDO V.; LORAND-METZE, IRENE; RAMOS, CELSO D. Proposal for a Quantitative F-18-FDG PET/CT Metabolic Parameter to Assess the Intensity of Bone Involvement in Multiple Myeloma. SCIENTIFIC REPORTS, v. 9, NOV 11 2019. Web of Science Citations: 0.

Please report errors in scientific publications list by writing to: cdi@fapesp.br.